AKT1 and non-small cell lung carcinoma: The median OS time of all the patients was 15.33 months (95% CI, 13.81–16.85), and survival time was significantly improved in the advanced NSCLC patients with PI3K- and p-Akt-negative expression compared with the patients with positive expression [P13K: 17.70 months (95% CI, 15.11–20.28 months) vs. 13.43 months (95% CI, 11.83–15.02 months); P=0.004; and p-Akt: 17.13 months (95% CI, 14.93–19.34 months) vs. 13.07 months (95% CI, 11.32–14.82 months); P=0.007].